MARKER THERAPEUTICS, INC. Deferred Policy Acquisition Cost, Foreign Currency Translation Adjustment and Other
MARKER THERAPEUTICS, INC. (MRKR) reported Deferred Policy Acquisition Cost, Foreign Currency Translation Adjustment and Other of -$58.33 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2016-04-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther · last filed 2016-04-14
- MARKER THERAPEUTICS, INC. deferred policy acquisition cost, foreign currency translation adjustment and other for fiscal 2014 was -$58.33K, a 1860.23% decline from fiscal 2013.
- MARKER THERAPEUTICS, INC. deferred policy acquisition cost, foreign currency translation adjustment and other for fiscal 2013 was $3.31K.
| Period end | Deferred Policy Acquisition Cost, Foreign Currency Translation Adjustment and Other 12 month | Deferred Policy Acquisition Cost, Foreign Currency Translation Adjustment and Other 12 month as first filed |
|---|---|---|
| 2014-12-31 | -$58.33K 10-K · filed 2016-04-14 | $58.33K 10-K · filed 2015-04-15 |
| 2013-12-31 | $3.31K 10-K · filed 2015-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |